Publication | Closed Access

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Second-line TreatmentOncologyWild-type Egfr TumoursMetronomic TherapyPathologyBronchial NeoplasmErlotinib Versus DocetaxelCancer TreatmentMedicineRadiation OncologyLung CancerMolecular Oncology